The use of preimplantation genetic testing for aneuploidy (PGT-A): a committee opinion
Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Electronic address: ASRM@asrm.org, Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology, Alan Penzias, Kristin Bendikson, Samantha Butts, Christos Coutifaris, Tommaso Falcone, Gregory Fossum, Susan Gitlin, Clarisa Gracia, Karl Hansen, Andrew La Barbera, Jennifer Mersereau, Randall Odem, Richard Paulson, Samantha Pfeifer, Margareta Pisarska, Robert Rebar, Richard Reindollar, Mitchell Rosen, Jay Sandlow, Michael Vernon, Eric Widra, Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Electronic address: ASRM@asrm.org, Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology, Alan Penzias, Kristin Bendikson, Samantha Butts, Christos Coutifaris, Tommaso Falcone, Gregory Fossum, Susan Gitlin, Clarisa Gracia, Karl Hansen, Andrew La Barbera, Jennifer Mersereau, Randall Odem, Richard Paulson, Samantha Pfeifer, Margareta Pisarska, Robert Rebar, Richard Reindollar, Mitchell Rosen, Jay Sandlow, Michael Vernon, Eric Widra
Abstract
The value of preimplantation genetic testing for aneuploidy (PGT-A) as a screening test for in vitro fertilization (IVF) patients has yet to be determined. Several studies demonstrate higher birth rates after aneuploidy testing and elective single-embryo transfer (eSET), suggesting the potential for this testing to decrease the risk of multiple gestations, though these studies have important limitations.
Copyright © 2018 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
Source: PubMed